Edition:
United Kingdom

ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

0.39USD
22 Mar 2019
Change (% chg)

$-0.02 (-5.20%)
Prev Close
$0.41
Open
$0.40
Day's High
$0.41
Day's Low
$0.37
Volume
83,364
Avg. Vol
131,482
52-wk High
$1.27
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Arca Biopharma Has Cash And Cash Equivalents Totaling $6.6 Mln (Unaudited) As Of Dec. 31
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA INC - AS OF DECEMBER 31, 2018, HAD CASH AND CASH EQUIVALENTS TOTALING $6.6 MILLION (UNAUDITED).ARCA BIOPHARMA INC - BELIEVES THAT FUNDS WILL BE SUFFICIENT TO FUND ITS OPERATIONS, AT ITS PROJECTED COST STRUCTURE, THROUGH END OF Q2 OF 2019..  Full Article

Arca Biopharma Inc - Gencaro Development Program Has FDA Fast Track Designation
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3 CLINICAL TRIAL TO SUPPORT APPROVAL FOR THE FIRST GENETICALLY-TARGETED CARDIOVASCULAR DRUG.ARCA BIOPHARMA INC - 58% TREATMENT BENEFIT SEEN VERSUS ACTIVE COMPARATOR IN PHASE 2B FOR PLANNED PHASE 3 TARGET POPULATION.ARCA BIOPHARMA INC - GENCARO DEVELOPMENT PROGRAM HAS FDA FAST TRACK DESIGNATION.ARCA BIOPHARMA INC - U.S. AND EUROPEAN CARDIOVASCULAR PATENTS AND REGULATIONS MAY PROVIDE COMMERCIAL EXCLUSIVITY FOR GENCARO FOR 10 YEARS POST APPROVAL.  Full Article

Arca Biopharma Updates Special Protocol Assessment Request To FDA
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL.ARCA BIOPHARMA INC - PHASE 3 ATRIAL FIBRILLATION TRIAL PLANNED IN POPULATION WITH NO EFFECTIVE OR FDA APPROVED THERAPIES.ARCA BIOPHARMA INC - PHASE 3 ATRIAL FIBRILLATION TRIAL PLANNED IN POPULATION WITH NO EFFECTIVE OR FDA APPROVED THERAPIES.ARCA BIOPHARMA INC - ARCA ANTICIPATES INITIATING PRECISION-AF IN SECOND HALF OF 2019.  Full Article

Arca Biopharma Announces Positive Outcome Of End-Of-Phase 2 Meeting With FDA On Gencaro Development For Atrial Fibrillation
Tuesday, 31 Jul 2018 

July 31 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES POSITIVE OUTCOME OF END-OF-PHASE 2 MEETING WITH FDA ON GENCARO DEVELOPMENT FOR ATRIAL FIBRILLATION.ARCA BIOPHARMA INC - SINGLE PHASE 3 TRIAL MAY BE SUFFICIENT FOR APPROVAL OF ATRIAL FIBRILLATION INDICATION.ARCA BIOPHARMA INC - PHASE 3 CLINICAL TRIAL SPECIAL PROTOCOL ASSESSMENT SUBMISSION ANTICIPATED 3Q2018.ARCA BIOPHARMA - FDA SUGGESTED CO SUBMIT SPA APPLICATION, WHICH CO ANTICIPATES SUBMITTING IN Q3 2018.ARCA - EXPECTS INITIATING PHASE 3 CLINICAL TRIAL SUBJECT TO SECURING MORE FINANCING BY STRATEGIC PARTNERSHIP AND/OR ADDITIONAL SALES OF SECURITIES.  Full Article

Arca Biopharma Q1 Loss Per Share $0.20
Tuesday, 8 May 2018 

May 8 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.20.  Full Article

Arca Biopharma announces issuance of European patent on cardiovascular disease treatment methods
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Arca Biopharma Inc :Arca Biopharma announces issuance of European patent for treating cardiovascular diseases and conditions with a new chemical entity utilizing genetic targeting.Arca Biopharma- believes current cash, cash equivalents,marketable securities will be sufficient to fund its operations through end of Q2 of 2018​.  Full Article

ARCA Biopharma announces third quarter financial results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Arca Biopharma Inc :ARCA Biopharma announces third quarter 2017 financial results and provides business update.Q3 loss per share $0.39.ARCA Biopharma Inc - anticipate reporting top-line data for Genetic-AF clinical trial​ late in Q1 of 2018.ARCA Biopharma Inc - ‍expects research and development expenses in 2017 to be higher than 2016​.  Full Article